story of the week
ESR1 Mutation Prevalence and Genomic Landscape Alterations in CDK4/6i-Treated HR+/HER2− Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
NPJ Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape
NPJ Breast Cancer 2024 Feb 22;10(1)15, N Chaudhary, AM Chibly, A Collier, J Martinalbo, P Perez-Moreno, HM Moore, P Luhn, C Metcalfe, M HafnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.